UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 115

Sortiert nach

Analysis of Single-Cell RNA-Seq Identifies Cell-Cell Communication Associated with Tumor Characteristics

Cell reports (Cambridge), 2018-11, Vol.25 (6), p.1458-1468.e4

2018

Volltextzugriff (PDF)

Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion

Cancer research (Chicago, Ill.), 2014-12, Vol.74 (23), p.7003-7013

2014

Volltextzugriff (PDF)

Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study

Clinical cancer research, 2017-07, Vol.23 (14), p.3638-3648

2017

Volltextzugriff (PDF)

Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development

Journal of pharmaceutical sciences, 2008-11, Vol.97 (11), p.4696-4740

2008

Volltextzugriff (PDF)

Targeted Tumor Cell Internalization and Imaging of Multifunctional Quantum Dot-Conjugated Immunoliposomes in Vitro and in Vivo

Nano letters, 2008-09, Vol.8 (9), p.2851-2857

2008

Volltextzugriff (PDF)

Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs

Journal of controlled release, 2019-09, Vol.310, p.47-57

2019

Volltextzugriff (PDF)

Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy

Cancer research (Chicago, Ill.), 2006-03, Vol.66 (6), p.3271-3277

2006

Volltextzugriff (PDF)

Drug Stability and Minimized Acid-/Drug-Catalyzed Phospholipid Degradation in Liposomal Irinotecan

Journal of pharmaceutical sciences, 2023-02, Vol.112 (2), p.416-434

2023

Volltextzugriff (PDF)

Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo

Cancer research (Chicago, Ill.), 2005-12, Vol.65 (24), p.11631-11638

2005

Volltextzugriff (PDF)

Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models

Cancer research (Chicago, Ill.), 2006-07, Vol.66 (13), p.6732-6740

2006

Volltextzugriff (PDF)

Impact of Single-chain Fv Antibody Fragment Affinity on Nanoparticle Targeting of Epidermal Growth Factor Receptor-expressing Tumor Cells

Journal of molecular biology, 2007-08, Vol.371 (4), p.934-947

2007

Volltextzugriff (PDF)

New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model

Journal of neuro-oncology, 2018-02, Vol.136 (3), p.475-484

2018

Volltextzugriff (PDF)

Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression

Clinical cancer research, 2015-03, Vol.21 (5), p.1139-1150

2015

Volltextzugriff (PDF)

Synergy between EphA2-ILs-DTXp, a Novel EphA2-Targeted Nanoliposomal Taxane, and PD-1 Inhibitors in Preclinical Tumor Models

Molecular cancer therapeutics, 2020-01, Vol.19 (1), p.270-281

2020

Volltextzugriff (PDF)

Development of disulfide-stabilized Fabs for targeting of antibody-directed nanotherapeutics

mAbs, 2022, Vol.14 (1), p.2083466-2083466

2022

Volltextzugriff (PDF)

Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer

Clinical cancer research, 2018-06, Vol.24 (12), p.2873-2885

2018

Volltextzugriff (PDF)

Nanoliposome targeting in breast cancer is influenced by the tumor microenvironment

Nanomedicine, 2019-04, Vol.17, p.71-81

2019

Volltextzugriff (PDF)

Development of a highly stable and targetable nanoliposomal formulation of topotecan

Journal of controlled release, 2010-01, Vol.141 (1), p.13-21

2010

Volltextzugriff (PDF)

Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer

Scientific reports, 2019-11, Vol.9 (1), p.16832-10, Article 16832

2019

Volltextzugriff (PDF)

Report of the AAPS Guidance Forum on the FDA Draft Guidance for Industry: “Drug Products, Including Biological Products, that Contain Nanomaterials”

The AAPS journal, 2019-04, Vol.21 (4), p.56, Article 56

2019

Volltextzugriff (PDF)

Current status of pH-sensitive liposomes in drug delivery

Progress in lipid research, 2000-09, Vol.39 (5), p.409-460

2000

Volltextzugriff (PDF)

HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity

Toxicology and applied pharmacology, 2012-07, Vol.262 (1), p.1-10

2012

Volltextzugriff (PDF)

Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer

Anti-cancer drugs, 2017-11, Vol.28 (10), p.1086-1096

2017

Volltextzugriff (PDF)

Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells

Cancer research (Chicago, Ill.), 2003-06, Vol.63 (12), p.3154-3161

2003

Volltextzugriff (PDF)

Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors : Pharmacology and efficacy

Cancer research (Chicago, Ill.), 2006-03, Vol.66 (5), p.2801-2806

2006

Volltextzugriff (PDF)

1 – 25 von 115

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(111)
Mit Volltextzugriff
(105)

Publikationsform

Sprache

Englisch
(115)
Japanisch
(27)

Erscheinungsjahr

n.n

Thema

Science & Technology
(71)
Life Sciences & Biomedicine
(67)
Humans
(47)
Animals
(40)
Liposomes
(29)
Oncology
(26)
Female
(23)
Mice
(21)
Biological And Medical Sciences
(20)
Cell Line, Tumor
(19)
Medical Sciences
(18)
Male
(16)
Liposome
(15)
Pharmacology & Pharmacy
(15)
Antineoplastic Agents - Administration & Dosage
(14)
Neurosciences & Neurology
(13)
Pharmacology. Drug Treatments
(13)
Rats
(13)
Camptothecin - Analogs & Derivatives
(12)
Nanoparticles
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Analysis of Single-Cell RNA-Seq Identifies Cell-Cell Communication Associated with Tumor Characteristics

Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion

Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study

Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development

Targeted Tumor Cell Internalization and Imaging of Multifunctional Quantum Dot-Conjugated Immunoliposomes in Vitro and in Vivo

Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs

Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy

Drug Stability and Minimized Acid-/Drug-Catalyzed Phospholipid Degradation in Liposomal Irinotecan

Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo

Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models

Impact of Single-chain Fv Antibody Fragment Affinity on Nanoparticle Targeting of Epidermal Growth Factor Receptor-expressing Tumor Cells

New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model

Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression

Synergy between EphA2-ILs-DTXp, a Novel EphA2-Targeted Nanoliposomal Taxane, and PD-1 Inhibitors in Preclinical Tumor Models

Development of disulfide-stabilized Fabs for targeting of antibody-directed nanotherapeutics

Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer

Nanoliposome targeting in breast cancer is influenced by the tumor microenvironment

Development of a highly stable and targetable nanoliposomal formulation of topotecan

Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer

Report of the AAPS Guidance Forum on the FDA Draft Guidance for Industry: “Drug Products, Including Biological Products, that Contain Nanomaterials”

Current status of pH-sensitive liposomes in drug delivery

HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity

Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer

Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells

Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors : Pharmacology and efficacy

Suchergebnisse filtern